β-cell apoptosis in type 2 diabetes: quantitative and functional consequences

Diabetes and Metabolism

Volumn 34, Issue SUPPL. 2, 2008, Pages

  Lupi, R ^a   Del Prato, S ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Apoptosis; Pancreatic cells; Type 2 diabetes

Indexed keywords

AMYLIN; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSAMINE PHOSPHATE ACETYLTRANSFERASE; GLUCOSE; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; INSULIN; METFORMIN; SULFONYLUREA;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIVISION; CELL VOLUME; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; QUANTITATIVE ANALYSIS;

ADMINISTRATION, ORAL; AMYLOID; APOPTOSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; SULFONYLUREA COMPOUNDS;

EID: 47149095278     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(08)73396-2     Document Type: Article

References (94)

1. Kudva Y.C., and Butler P.C. Insulin secretion in type-2 diabetes mellitus. In: Draznin B., and Rizza R. (Eds). Clinical Research in Diabetes and Obesity. Diabetes and Obesity (1997), Humana Press, Totowa, NJ 119-136
2. DeFronzo R.A. Lilly Lecture 1987: the triumvirate: cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37 (1988) 667-687
3. Scheen A.J. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?. Diabetes Metab 31 (2005) 5S27-5S34
4. Reaven G.M. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am 34 (2005) 49-62
5. Matthews D.R. The natural history of diabetes-related complications: the UKPDS experience. United Kingdom Prospective Diabetes Study. Diabetes Obes Metab 1 (1999) S7-S13
6. Meyer C., Pimenta W., Woerle H.J., et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29 (2006) 1909-1914
7. Levy J., Atkinson A.B., Bell P.M., McCance D.R., and Hadden D.R. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15 (1998) 290-296
8. Guiot Y., Sempoux C., Moulin P., and Rahier J. No decrease of the beta-cell mass in type 2 diabetic patients. Diabetes 50 Suppl. 1 (2001) S188
9. Stefan Y., Orci L., Malaisse-Lagae F., Perrelet A., Patel Y., and Unger R.H. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 31 (1982) 694-700
10. Rahier J., Goebbels R.M., and Henquin J.C. Cellular composition of the human diabetic pancreas. Diabetologia 24 (1983) 366-371
11. Del Guerra S., Lupi R., Marselli L., et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 54 (2005) 727-735
12. Marchetti P., Del Guerra S., Marselli L., et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89 (2004) 5535-5541
13. Burns N., Finucane F.M., Hatunic M., et al. Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 50 (2007) 1500-1508
14. Butler A.E., Janson J., Soeller W.C., and Butler P.C. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52 (2003) 2304-2314
15. Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr Med Res Opin 23 (2007) 933-944
16. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28 (2007) 187-218
17. Pick A., Clark J., Kubstrup C., Levisetti Mpugh W., Bonner-Weir S., and Polonsky K.S. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47 (1998) 358-364
18. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
19. Wajant H. The Fas signaling pathway: more than a paradigm. Science 296 (2002) 1635-1636
20. Curtin J.F., and Cotter T.G. Live and let die: regulatory mechanisms in Fasmediated apoptosis. Cell Signal 15 (2003) 983-992
21. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat Med 10 (2004) S18-S25
22. Gibson G.E., and Huang H.M. Mitochondrial enzymes and endoplasmic reticulum calcium stores as targets of oxidative stress in neurodegenerative diseases. J Bioenerg Biomembr 36 (2004) 335-340
23. Schroder M., and Kaufman R.J. ER stress and the unfolded protein response. Mutat Res 569 (2005) 29-63
24. Ferri K.F., and Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 3 (2001) E255-E263
25. Kaiser N., Leibowitz G., and Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 16 (2003) 5-22
26. Del Guerra S., Grupillo M., Masini M., et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 23 (2007) 234-238
27. D'Alessandris C., Andreozzi F., Federici M., et al. Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells. FASEB J 18 (2004) 959-961
28. Kralik S.F., Liu P., Leffler B.J., and Elmendorf J.S. Ceramide and glucosamine antagonism of alternate signaling pathways regulating insulin- and osmotic shock-induced glucose transporter 4 translocation. Endocrinology 143 (2002) 37-46
29. Atkinson M.A., and Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358 (2001) 221-229
30. Rabinovitch A., and Suarez-Pinzon W.L. Roles of cytokines in the pathogenesis and therapy of type 1 diabetes. Cell Biochem Biophys 48 (2007) 159-163
31. Maedler K., Sergeev P., Ris F., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110 (2002) 851-860
32. Welsh N., Cnop M., Kharroubi I., et al. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?. Diabetes 54 (2005) 3238-3244
33. Maedler K., and Donath M.Y. Beta-cells in type 2 diabetes: a loss of function and mass. Horm Res 62 (2004) 67-73
34. Maedler K., Spinas G.A., Lehmann R., et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50 (2001) 1683-1690
35. Harding H.P., and Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 51 (2002) S455-S461
36. Deleted.
37. Zhang K., and Kaufman R.J. Protein folding in the endoplasmic reticulum and the unfolded protein response. Handb Exp Pharmacol 172 (2006) 69-91
38. Marchetti P., Bugliani M., Lupi R., et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50 (2007) 2486-2494
39. Ronti T., Lupattelli G., and Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 64 (2006) 355-365
40. Maedler K., Sergeev P., Ehses J.A., et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 101 (2004) 8138-8143
41. Maedler K., Oberholzer J., Bucher P., Spinas G.A., and Donath M.Y. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 52 (2003) 726-733
42. Lupi R., Dotta F., Marselli L., et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51 (2002) 1437-1442
43. Wrede C.E., Dickson L.M., Lingohr M.K., Briaud I., and Rhodes C.J. Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J Biol Chem 277 (2002) 49676-49684
44. Shimabukuro M., Zhou Y.T., Levi M., and Unger R.H. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 95 (1998) 2498-2502
45. Shimabukuro M., Ohneda M., Lee Y., and Unger R.H. Role of nitric oxide in obesity induced beta cell disease. J Clin Invest 100 (1997) 290-295
46. Poitout V., and Robertson R.P. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr Rev (2007) Nov 29 [Epub ahead of print]
47. Lukinius A., Wilander E., Westermark G.T., Engstrom U., and Westermark P. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32 (1989) 240-244
48. Kahn S.E., Verchere C.B., Andrikopoulos S., et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47 (1998) 640-645
49. Enoki S., Mitsukawa T., Takemura J., Nakazato, et al. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15 (1992) 97-102
50. Leighton B., and Cooper C.J.S. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335 (1988) 632-635
51. Silvestre R.A., Peiró E., Dégano P., Miralles P., and Marco J. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 31 (1990) 23-31
52. Cooper G.J.S., Day A.J., Willis A.C., Roberts A.N., Reid K.B.M., and Leighton B. Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus. Biochem Biophys Acta 1014 (1989) 247-258
53. Sempoux C., Guiot Y., Dubois D., Moulin P., and Rahier J. Human type 2 diabetes: Morphological evidence for abnormal beta-cell function. Diabetes 50 (2001) S172-S177
54. Bernard-Kargar C., and Ktorza A. Endocrine pancreas plasticity under physiological and pathological conditions. Diabetes 50 (2001) S30-S35
55. Porte Jr. D. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev 17 (2001) 181-188
56. Kahn S.E., Andrikopoulos S., and Verchere C.B. Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48 (1999) 241-253
57. Finegood D., and Topp B. β-cell deterioration -prospects for reversal or prevention. Diabetes Obes Metab 3 (2001) S20-S27
58. Hayden M., and Tyagi S. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. Pancreas 3 (2002) 86-108
59. Janson J., Ashley R., Harrison D., McIntyre S., and Butler P. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48 (1999) 491-498
60. Lorenzo A., Razzaboni B., Weir G.C., and Yankner B.A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368 (1994) 756-760
61. Wang F., Hull R., Vidal J., Cnop M., and Kahn S. Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50 (2001) 2514-2520
62. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
63. Heald A.H., Anderson S.G., Patel J., et al. Change in pancreatic B-cell function (HOMA-B) varies in different populations with similar genetic backgrounds but different environments. Diabet Med 24 (2007) 145-153
64. Takahashi A., Nagashima K., Hamasaki A., et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract 77 (2007) 343-350
65. Maedler K., Carr R.D., Bosco D., Zuellig R.A., Berney T., and Donath M.Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90 (2005) 501-506
66. Efanova I.B., Zaitsev S.V., Zhivotovsky B., et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 273 (1998) 33501-33507
67. Del Guerra S., Marselli L., Lupi R., et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications 19 (2005) 60-64
68. Dor Y., Brown J., Martinez O.I., and Melton D.A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429 (2004) 41-46
69. Bonner-Weir S., and Weir G.C. New sources of pancreatic beta-cells. Nat Biotechnol 23 (2005) 857-861
70. Del Prato S., Wishner W.J., Gromada J., and Schluchter B.J. Beta-cell mass plasticity in type 2 diabetes. Diabetes Obes Metab 6 (2004) 319-331
71. Pick A., Clark J., Kubstrup C., Levisetti M., et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47 (1998) 358-364
72. Westermark P., and Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15 (1978) 417-421
73. Saito K., Iwama N., and Takahashi T. Morphometrical analysis on topographical difference in size distribution, number and volume of islets in the human pancreas. Tohoku J Exp Med 124 (1978) 177-186
74. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
75. Marchetti P., Del Guerra S., Marselli L., et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89 (2004) 5535-5541
76. Kendall D.M., Sutherland D.E., Najarian J.S., Goetz F.C., and Robertson R.P. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 322 (1990) 898-903
77. Weir G.C., Leahy J.L., and Bonner-Weir S. Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev 2 (1986) 125-161
78. Kjems L.L., Kirby B.M., Welsh E.M., et al. Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonaemia in the minipig. Diabetes 50 (2001) 2001-2012
79. Stagner J.I., and Samols E. Deterioration of islet beta-cell function after hemipancreatectomy in dogs. Diabetes 40 (1991) 1472-1479
80. Goodner C.J., Koerker D.J., Weigle D.S., and McCulloch D.K. Decreased insulin- and glucagon-pulse amplitude accompanying beta-cell deficiency induced by streptozocin in baboons. Diabetes 38 (1989) 925-931
81. Matveyenko A.V., Veldhuis J.D., and Butler P.C. Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 55 (2006) 2347-2356
82. Nielsen J.H., Galsgaard E.D., Møldrup A., et al. Regulation of beta-cell mass by hormones and growth factors. Diabetes 50 (2001) S25-S29
83. Perley M.J., and Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46 (1967) 1954-1962
84. Mirouze J., Orsetti A., and Lapinski H. Plasma insulin responses to oral and venous glucose in various forms of diabetes mellitus. Acta Diabetol Lat 7 (1970) 55-67
85. D'Alessio D.A., Kahn S.E., Leusner C.R., and Ensinck J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93 (1994) 2263-2266
86. Perfetti R., and Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 36 (2004) 804-810
87. Xu G., Stoffers D.A., Habener J.F., and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
88. Stoffers D.A., Kieffer T.J., Hussain M.A., et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 (2000) 741-748
89. Farilla L., Hui H., Bertolotto C., et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
90. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., and Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 (2003) 471-478
91. Hui H., Nourparvar A., Zhao X., and Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144 (2003) 1444-1455
92. Farilla L., Bulotta A., Hirshberg B., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003) 5149-5158
93. Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol 31 (2006) 133-147
94. Baggio L.L., and Drucker D.J. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57 (2006) 265-281